Skip to main content

Table 3 Follow-up, vital status and cause of death for patients with endometrial cancer after breast cancer, by study

From: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries

  Study Combined
  NL UK US   
Number of subjects 765 786 324 1875
Total follow-up time (person-years) 2,676.6 5,552.2 2,731.5 10,960.3
Maximum follow-up (years) 16.6 20.3 25.5 25.5
Median length of follow-up (years) 2.6 5.2 8.1 4.0
Vital status at end of follow-up (n, %)
   Alive 470 61.4% 202 26% 99 31% 771 41.1%
   Deceased 295 38.6% 584 74% 225 69% 1,104 58.9%
Cause of death (n, %)         
   Breast cancer 92 31% 198 34% 63 28% 353 32.0%
   Endometrial cancer 85 29% 151 26% 41 18% 277 25.1%
   Breast or cancera 28 9% 9 2% 0 0% 37 3.4%
   All other causesb, c 90 31% 226 39% 121 54% 437 39.6%
   All causes 295 100% 584 100% 225 100% 1,104 100.0%
Survival (95% CI): all cause mortality
   1-year survival 87%
(84%, 89%)
81%
(78%, 83%)
87%
(83%, 90%)
84.4%
(82.7%, 86.0%)
   5-year survival 57%
(53%, 61%)
51%
(48%, 55%)
61%
(56%, 66%)
55.5%
(53.1%, 57.9%)
Survival (95% CI): endometrial cancer mortalityd
   1-year survival 93%
(91%, 95%)
89%
(87%, 91%)
94%
(91%, 96%)
91.8%
(90.5%, 93.0%)
   5-year survival 86%
(83%, 88%)
81%
(78%, 84%)
87%
(82%, 90%)
83.8%
(81.9%, 85.6%)
  1. aNot possible to differentiate between breast and endometrial cancer as cause of death; b15 (2.6%) patients in UK and 4 (1.8%) in the USA study had cancer as cause of death, but primary site unknown; c4 (1.4%) patients in NL and 2 (0.3%) in UK study had an unknown cause of death; ddeaths due to causes other than endometrial cancer are censored on date of death. CI, confidence interval; n, number.